Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.38 |
| ▸ | CHRNG | P07510 | 1/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.38 |
| ▸ | CHRND | Q07001 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3740365 | 0.94 | SRC (0.49) | SRCITGB3ITGA2BCHRNA1CHRNG | |
| SCHEMBL3745655 | 0.93 | SRC (0.51) | SRCITGB3ITGA2BMMP8CHRNA1 | |
| SCHEMBL3742633 | 0.92 | SRC (0.49) | SRCITGB3ITGA2BMMP8MMP1 | |
| SCHEMBL3741713 | 0.90 | SRC (0.54) | SRCITGB3ITGA2BMMP8ALDH1A1 | |
| SCHEMBL3738151 | 0.89 | SRC (0.52) | SRCMMP8CHRNA1CHRNGCHRNB1 | |
| SCHEMBL3748684 | 0.89 | SRC (0.50) | SRCMMP8CHRNA1CHRNGCHRNB1 | |
| SCHEMBL3738294 | 0.88 | SRC (0.51) | SRCCHRNA1CHRNGCHRNB1CHRND | |
| SCHEMBL3742611 | 0.87 | TSHR (0.54) | SRCITGB3ITGA2BMMP8ALDH1A1 | |
| SCHEMBL3730068 | 0.85 | NPY5R (0.54) | SRCALDH1A1MAPTMMP2MMP9 | |
| SCHEMBL3740548 | 0.85 | MMP2 (0.48) | SRCALDH1A1MAPTMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829737-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7504389-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | FALCON TECHNOLOGY PARTNERS L.P. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PPM1B, PTPN1, PTPN5 | SRC 174/4885ITGB3 4528/4885ITGA2B 3660/4885 |
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | PPM1B, PTPN1, PTPN5 | SRC 174/4885ITGB3 4528/4885ITGA2B 3660/4885 |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PPM1B, PTPN1, PTPN5 | SRC 174/4885ITGB3 4528/4885ITGA2B 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.